CLINICAL TRIALS PROFILE FOR TIRZEPATIDE
✉ Email this page to a colleague
All Clinical Trials for TIRZEPATIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03131687 ↗ | A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus | Completed | Eli Lilly and Company | Phase 2 | 2017-05-24 | The purpose of this study is to evaluate the efficacy of the study drug tirzepatide in participants with type 2 diabetes mellitus. |
| NCT03311724 ↗ | A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes | Completed | Eli Lilly and Company | Phase 2 | 2017-10-19 | The purpose of this study is to determine the efficacy of tirzepatide in participants with type 2 diabetes. |
| NCT03322631 ↗ | A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes | Completed | Eli Lilly and Company | Phase 1 | 2017-11-15 | The purposes of this study are to determine: - The safety of tirzepatide and any side effects that might be associated with it. - How much tirzepatide gets into the bloodstream and how long it takes the body to remove it. - How tirzepatide affects the levels of blood sugar. This study includes eight weekly doses of tirzepatide or placebo given as subcutaneous (SC) injections just under the skin. The study will last about 16 weeks (total), including screening and follow-up. This study is for research purposes only and is not intended to treat any medical conditions. |
| NCT03375463 ↗ | A Study of Tirzepatide (LY3298176) in Healthy Participants | Completed | Eli Lilly and Company | Phase 1 | 2017-12-19 | This study has three parts. Each participant will enroll in one part. Part A: The purpose of Part A is to compare study drug tirzepatide solution formulation to a powder formulation mixed with water and given subcutaneously (SC) (just under the skin). Part A will measure how much of the study drug gets into the blood stream and how long it takes the body to get rid of it. Part B: The purpose of Part B is to evaluate the safety and tolerability of tirzepatide intravenous (IV) formulation when administered into a vein. Part C: The purpose of Part C is to evaluate the safety and tolerability of tirzepatide following multiple SC weekly doses of a solution. This study will last approximately 70 days for Part A or Part B and 92 days for Part C. This does not include screening. Screening is required within 28 days prior to the start of the study. |
| NCT03482024 ↗ | A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function | Completed | Eli Lilly and Company | Phase 1 | 2018-03-30 | The purpose of this study is to assess how fast tirzepatide gets into the blood stream and how long it takes the body to remove it in participants with impaired kidney function compared to healthy participants. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TIRZEPATIDE
Condition Name
Clinical Trial Locations for TIRZEPATIDE
Trials by Country
Clinical Trial Progress for TIRZEPATIDE
Clinical Trial Phase
Clinical Trial Sponsors for TIRZEPATIDE
Sponsor Name
